Trial Summary
What is the purpose of this trial?
The purpose of this study is to to compare photodynamic therapy (PDT) versus the combination of Jessner's solution and 35% trichloroacetic acid (TCA) chemical peels for the treatment of actinic keratoses on upper extremities. This is a randomized clinical trial. Approximately 60 participants with actinic keratoses on both upper arms will be randomized to have one arm receive photodynamic therapy, while the contralateral arm receives Jessner's solution followed immediately by 35% TCA. AKs will be counted before treatment and 2-8 weeks after treatment. This study is a pilot study designed to determine the feasibility of this procedure. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.
Research Team
Murad Alam, MD
Principal Investigator
Northwestern University
Eligibility Criteria
This trial is for adults over 18 in the Chicago area who want to treat actinic keratoses on both upper arms and are in good health. They must understand and sign a consent form. Pregnant or nursing individuals, those with communication issues, or extensive skin conditions like eczema or psoriasis on their arms cannot participate.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Chemical Peels (Other)
- Photodynamic Therapy (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor
Dr. Jeffrey Sherman
Northwestern University
Chief Medical Officer
MD from Northwestern University
Dr. Alicia Löffler
Northwestern University
Chief Executive Officer since 2010
PhD from the University of Massachusetts at Amherst, post-doctoral training at Caltech